Emcure Pharma
Latest news, explainers and analysis on Emcure Pharma. Tracking 2 stories on Arth Vani.
Connected in the graph
Latest on Emcure Pharma
BreakingEmcure Pharma Shares Surge 10% on Strong Q2 FY27 Results; Guidance Raised
Emcure Pharma shares surged by 10% to hit the upper circuit after the company reported robust Q2 FY27 results and increased its full-year growth guidance. This positive outlook, driven by strong international sales and a promising product pipeline, led brokerages like Jefferies to raise their target price for the stock.

Kotak Mutual Fund Invests ₹612 Crore in Emcure Pharma; PE Firm BC Investments Exits
Private equity firm BC Investments IV has sold its stake in Emcure Pharmaceuticals to Kotak Mutual Fund for ₹612 crore. This major transaction highlights growing institutional confidence in Emcure's growth potential across key medical segments.
Mutual fund data is sourced from AMFI and shown for information only — funds are subject to market risks. Read all scheme-related documents carefully. Some listings may be sponsored. Not investment advice.